Replimune Group, Inc.

NASDAQ:REPL

Biotechnology

Healthcare
$19.81 +1.85%

+$0.19 today

Market cap
$1.88B
Beta
0.91
P/E (TTM)
-3.0
EPS (TTM)
-$3.42
52W Low $1.50High $13.24

Volume 2.13M

Average 7.51M

REPL Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Replimune Group, Inc.NASDAQ: REPL

Accounts Receivables · Q3 FY2026 · quarter ended Dec 2025

Accounts receivables declines year over year

Q3 FY2026 accounts receivables of $349K (cash outflow) fell 7.4% year over year, ahead of the -70.4% change in trailing-twelve-month accounts receivables. Sequentially, it fell 4.9% from the prior quarter.

Context

  • Accounts receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -7.4% holds above the trailing-twelve-month pace of -70.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$349K-4.9% QoQ
Last fiscal yearMar 2025
$1.3M+168.0% YoY
LTMDec 2025
$354K-70.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.4%——
1 year+168.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
1.3M USD
Year-over-year change
+168.0%
4-year CAGR
+41.5%

Accounts Receivables vs competitors

How REPL compares with its peers on the latest reported figures

  • REPL's LTM Dec 2025 accounts receivables of $354K is the 6th largest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -70.4% is the 5th highest of 7, against a peer median of +40.5%.
REPL Competitors Peer median
Accounts Receivables for REPL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$40.23M +265.9%—10.6%
JANXJanux Therapeutics, Inc.LTM Mar 2026$35M +401.4%—161.9%
IBRXImmunityBio, Inc.LTM Sep 2026$21.58M -22.5%—11.8%
AGENAgenus Inc.LTM Mar 2026$6.57M -6016.2%—5.3%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$1.31M -88.3%—3.7%
REPLReplimune Group, Inc.LTM Dec 2025$354K -70.4%——
MGNXMacroGenics, Inc.LTM Mar 2026$117K +103.5%-41.7%0.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 ——0.0%
LYELLyell Immunopharma, Inc.LTM Mar 2026$0 ——0.0%
CGENCompugen Ltd.LTM Dec 2025$0 —-50.9%0.0%
ADAGAdagene Inc.LTM Jun 2024$0 ——0.0%
Peer median (excluding REPL) $0+40.5%-46.3%1.9%

Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Mar 2021
FY2022
Mar 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
Net Income(80.87M)(118.04M)(174.28M)(215.79M)(247.3M)
Depreciation & Amortization1.71M2.15M2.45M2.66M3.5M
Deferred Income Tax0038K00
Stock-Based Compensation11.79M24.25M28.13M34.13M35.04M
Change in Working Capital3.51M7.24M15.12M5.48M24.08M
Accounts Receivables325K(247K)(61K)(1.92M)1.3M
Inventory0247K61K00
Accounts Payables(1.03M)1.12M1.98M(2.79M)9.94M
Other Working Capital4.22M6.12M13.14M10.19M12.84M
Other Non-Cash Items2.47M2.22M494K(11.94M)(7.58M)
Operating Cash Flow(61.39M)(82.18M)(128.05M)(185.47M)(192.25M)
Capital Expenditures(2.39M)(2.34M)(2.27M)(5.66M)(6.69M)
Acquisitions (Net)0(530)140.23K00
Purchases of Investments(392.43M)(255.72M)(583.41M)(489.52M)(403.59M)
Sales of Investments206.05M256.25M443.18M592.38M386.48M
Other Investing Activities0530(140.23K)00
Investing Cash Flow(188.78M)(1.81M)(142.5M)97.2M(23.8M)
Debt Repayment(10.15M)(264K)27.79M14.52M(599K)
Common Stock Issued286.11M6.86M187.29M1.76M155.73M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities96.5M096.22M097.27M
Financing Cash Flow372.46M6.6M311.3M16.28M252.4M
Effect of Forex Changes721K818K(109K)(86K)315K
Net Change in Cash123.02M(76.57M)40.64M(72.07M)36.67M
Free Cash Flow(63.78M)(84.52M)(130.32M)(191.13M)(198.94M)

Replimune Group, Inc.

NASDAQ:REPL

Intrinsic Alpha fair value

Locked

Current Price

$19.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.